Template:Mesangial proliferative glomerulonephritis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue" |- | colspan="1" style="text-align:center; background:DarkGray" | '''M...")
 
No edit summary
 
Line 11: Line 11:
!
!
[[Mesangial proliferative glomerulonephritis|Home]]
[[Mesangial proliferative glomerulonephritis|Home]]
|-
|-
!
 
|- bgcolor="Pink"
!
[[Mesangial proliferative glomerulonephritis (patient information)|Patient Information]]
|-  
!
!


Line 23: Line 17:
!
!
[[Mesangial proliferative glomerulonephritis overview|Overview]]
[[Mesangial proliferative glomerulonephritis overview|Overview]]
|-
|-
!
 
|- bgcolor="Pink"
!
[[Mesangial proliferative glomerulonephritis historical perspective|Historical Perspective]]
|-
!
 
|- bgcolor="Pink"
!
[[Mesangial proliferative glomerulonephritis classification|Classification]]
|-  
!
!


Line 41: Line 23:
!
!
[[Mesangial proliferative glomerulonephritis pathophysiology|Pathophysiology]]
[[Mesangial proliferative glomerulonephritis pathophysiology|Pathophysiology]]
|-  
|-
!
!


Line 47: Line 29:
!
!
[[Mesangial proliferative glomerulonephritis causes|Causes]]
[[Mesangial proliferative glomerulonephritis causes|Causes]]
|-  
|-
!
!


Line 53: Line 35:
!
!
[[Mesangial proliferative glomerulonephritis differential diagnosis|Differentiating Mesangial proliferative glomerulonephritis from other Diseases]]
[[Mesangial proliferative glomerulonephritis differential diagnosis|Differentiating Mesangial proliferative glomerulonephritis from other Diseases]]
|-  
|-
!
!


Line 59: Line 41:
!
!
[[Mesangial proliferative glomerulonephritis epidemiology and demographics|Epidemiology and Demographics]]
[[Mesangial proliferative glomerulonephritis epidemiology and demographics|Epidemiology and Demographics]]
|-  
|-
!
!


Line 65: Line 47:
!
!
[[Mesangial proliferative glomerulonephritis risk factors|Risk Factors]]
[[Mesangial proliferative glomerulonephritis risk factors|Risk Factors]]
|-
|-
!
 
|- bgcolor="Pink"
!
[[Mesangial proliferative glomerulonephritis screening|Screening]]
|-  
!
!


Line 77: Line 53:
!
!
[[Mesangial proliferative glomerulonephritis natural history, complications and prognosis|Natural History, Complications and Prognosis]]
[[Mesangial proliferative glomerulonephritis natural history, complications and prognosis|Natural History, Complications and Prognosis]]
|-  
|-
!
!


Line 83: Line 59:
!
!
Diagnosis
Diagnosis
|-  
|-
!
!


Line 89: Line 65:
!
!
[[Mesangial proliferative glomerulonephritis history and symptoms|History and Symptoms]]
[[Mesangial proliferative glomerulonephritis history and symptoms|History and Symptoms]]
|-  
|-
!
!


Line 95: Line 71:
!
!
[[Mesangial proliferative glomerulonephritis physical examination|Physical Examination]]
[[Mesangial proliferative glomerulonephritis physical examination|Physical Examination]]
|-  
|-
!
!


Line 101: Line 77:
!
!
[[Mesangial proliferative glomerulonephritis laboratory findings|Laboratory Findings]]
[[Mesangial proliferative glomerulonephritis laboratory findings|Laboratory Findings]]
|-
|-
!
 
|- bgcolor="LightSkyBlue"
!
[[Mesangial proliferative glomerulonephritis electrocardiogram|Electrocardiogram]]
|-
!
 
|- bgcolor="LightSkyBlue"
!
[[Mesangial proliferative glomerulonephritis chest x ray|Chest X Ray]]
|-  
!
!


Line 119: Line 83:
!
!
[[Mesangial proliferative glomerulonephritis CT|CT]]
[[Mesangial proliferative glomerulonephritis CT|CT]]
|-  
|-
!
!


Line 125: Line 89:
!
!
[[Mesangial proliferative glomerulonephritis MRI|MRI]]
[[Mesangial proliferative glomerulonephritis MRI|MRI]]
|-  
|-
!
!


|- bgcolor="LightSkyBlue"
|- bgcolor="LightSkyBlue"
!
!
[[Mesangial proliferative glomerulonephritis echocardiography or ultrasound|Echocardiography or Ultrasound]]
[[Mesangial proliferative glomerulonephritis ultrasound|Ultrasound]]
|-  
|-
!
!


Line 137: Line 101:
!
!
[[Mesangial proliferative glomerulonephritis other imaging findings|Other Imaging Findings]]
[[Mesangial proliferative glomerulonephritis other imaging findings|Other Imaging Findings]]
|-  
|-
!
!


Line 143: Line 107:
!
!
[[Mesangial proliferative glomerulonephritis other diagnostic studies|Other Diagnostic Studies]]
[[Mesangial proliferative glomerulonephritis other diagnostic studies|Other Diagnostic Studies]]
|-  
|-
!
!


Line 149: Line 113:
!
!
Treatment
Treatment
|-  
|-
!
!


Line 155: Line 119:
!
!
[[Mesangial proliferative glomerulonephritis medical therapy|Medical Therapy]]
[[Mesangial proliferative glomerulonephritis medical therapy|Medical Therapy]]
|-  
|-
!
!


|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
[[Mesangial proliferative glomerulonephritis surgery|Surgery]]
[[Mesangial proliferative glomerulonephritis secondary prevention|Secondary Prevention]]
|-  
|-
!
!


|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
[[Mesangial proliferative glomerulonephritis primary prevention|Primary Prevention]]
[[Mesangial proliferative glomerulonephritis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]]
|-  
|-
!
 
|- bgcolor="PaleTurquoise"
!
!
[[Mesangial proliferative glomerulonephritis secondary prevention|Secondary Prevention]]
|-
!


|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
[[Mesangial proliferative glomerulonephritis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]]
[[Mesangial proliferative glomerulonephritis future or investigational therapies|Future or Investigational Therapies]]
|-  
|-
!
 
|- bgcolor="PaleTurquoise"
!
!
[[Mesangial proliferative glomerulonephritis future or investigational therapies|Future or Investigational Therapies]]
|-
!


|- bgcolor="CadetBlue"
|- bgcolor="CadetBlue"
!
!
Case Studies
Case Studies
|-  
|-
!
!


Line 197: Line 149:
!
!
[[Mesangial proliferative glomerulonephritis case study one|Case #1]]
[[Mesangial proliferative glomerulonephritis case study one|Case #1]]
|-  
|-
!
!


Line 203: Line 155:
!
!
{{PAGENAME}} On the Web
{{PAGENAME}} On the Web
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most recent articles]
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most recent articles]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://scholar.google.com/scholar?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=ps Most cited articles]
[http://scholar.google.com/scholar?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=ps Most cited articles]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D  Review articles]
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D  Review articles]
|-  
|-
!
!


Line 227: Line 179:
!
!
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:health_continuing_education&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col3&cd=2 CME Programs]
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:health_continuing_education&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col3&cd=2 CME Programs]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint slides]
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint slides]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images]
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images]
|-  
|-
!
!


Line 250: Line 202:
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} CT}}}} CT Images]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} CT}}}} CT Images]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} MRI}}}} MRI]
:[http://goldminer.arrs.org/search.php?query={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}} MRI}}}} MRI]
|-  
|-
!
!


Line 256: Line 208:
!
!
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials  at Clinical Trials.gov]
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials  at Clinical Trials.gov]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse]
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchType=guidance NICE Guidance]
[http://www.nice.org.uk/search/guidancesearchresults.jsp?keywords={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchType=guidance NICE Guidance]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.cdc.gov/search.do?queryText={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchButton.x=33&searchButton.y=6&action=search CDC on {{PAGENAME}}]
[http://www.cdc.gov/search.do?queryText={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&searchButton.x=33&searchButton.y=6&action=search CDC on {{PAGENAME}}]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the news]
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the news]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]</small>
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]</small>
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://maps.google.com/maps?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|map+top+hospital+Mesangial proliferative glomerulonephritis}}}}&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&ie=UTF-8&sa=N&hl=en&tab=wl Directions to Hospitals Treating Mesangial proliferative glomerulonephritis]
[http://maps.google.com/maps?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|map+top+hospital+Mesangial proliferative glomerulonephritis}}}}&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&ie=UTF-8&sa=N&hl=en&tab=wl Directions to Hospitals Treating Mesangial proliferative glomerulonephritis]
|-  
|-
!  
!


|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=QWo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+risk+score+OR+risk+calculator&btnG=Search Risk calculators and risk factors for {{PAGENAME}}]
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=QWo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+risk+score+OR+risk+calculator&btnG=Search Risk calculators and risk factors for {{PAGENAME}}]
|-  
|-
!  
!


|}
|}

Latest revision as of 16:59, 27 September 2012

Mesangial proliferative glomerulonephritis Microchapters

Home

Overview

Pathophysiology

Causes

Differentiating Mesangial proliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mesangial proliferative glomerulonephritis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mesangial proliferative glomerulonephritis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mesangial proliferative glomerulonephritis

CDC on Mesangial proliferative glomerulonephritis

Mesangial proliferative glomerulonephritis in the news

Blogs on Mesangial proliferative glomerulonephritis

Directions to Hospitals Treating Mesangial proliferative glomerulonephritis

Risk calculators and risk factors for Mesangial proliferative glomerulonephritis

Retrieved from "https://www.wikidoc.org/index.php?title=Template:Mesangial_proliferative_glomerulonephritis&oldid=759054"